Aller au contenu principal

Tous les comptes rendus : Études d'intervention

Études d'intervention

Intérêt de l’ajout du lixisenatide à une insuline basale

M. Puig-Domingo - Poster 908. Meta-Analysis of randomized controlled trials of lixisenatide as add-on to basal insulin and/or oral antidiabetic drugs in patients with type 2 diabetes mellitus.

Études d'intervention

La dapagliflozine en traitement add-on

S. Jabbour et coll. - P 938. Dapagliflozin helps reduce Hba1c and body weight in patients with type 2 diabetes as part of triple combination therapy: a subanalysis of four clinical studies.

Études d'intervention

Pas d’action cardiovasculaire péjorative de la saxagliptine à 2 ans

D. Bhatt - Saxagliptine Assessement of Vascular Outcomes Recorded in patients with type diabetes mellitus: SAVOR timi 53 Trial.

Études d'intervention

Cinq ans de recul pour l’exénatide

L. MacConnel et coll. - P 980. Efficacity and safety of Exenatide once weekly over 5 years.

Études d'intervention

Efficacité maintenue de l’exénatide à 3 ans

J. Malloy et coll. - Sustaining HbA1c control over three years during treatment with Exenatide once weekly compared with Insulin Glargine.

Études d'intervention

Dapagliflozine : des bénéfices secondaires importants

K. Rohwedder et coll. - Poster 939. Combined HbA1c and weight is more frequent with Dapagliflozin vs Glipizide add on treatment in patients with type 2 diabetes inadequately controlled on Metformine.